Professional Documents
Culture Documents
Review Article
Guidelines for the management of vitiligo
Afsheen Bilal, Irfan Anwar
Abstract Vitiligo is an acquired disorder of depigmentation affecting 0.1%-2% of the world’s population
without discrimination of race, age and gender. The disease is characterized by white patches, often
symmetrically distributed, which usually increase in size with time, corresponding to a considerable
loss of functioning epidermal and sometimes hair follicle melanocyte. There are many treatment
options available for the disease. Standardized guidelines for treating this disease in Asian skin are
not readily available which leads to no set criteria for treating this cosmetically disfiguring problem.
These guidelines have been prepared for dermatologists considering all the latest evidence based
data available. Vitiligo is diagnosed clinically, although in some cases biopsy is required. Lesions
on face and neck respond well to the treatment. However, segmental and acral types respond poorly
to treatment. In the assessment of patient before starting therapy it is important to consider age, pre-
existing diseases, in particular autoimmune disorders and previous medications. Topical
corticosteroids and/or topical immunomodulators for localized vitiligo and phototherapy for
generalized vitiligo are considered as first line therapies. As the treatment often extends over a long
period of time, patients are frequently frustrated by the failure of previous treatments, so
psychological stress is common and thus psychotherapy has also positive role. These
comprehensive guidelines for the diagnosis and management of vitiligo in coloured skin aims to
give high quality clinical advice, based on the best available evidence and expert consensus.
Key words
Vitiligo ,guidelines, management
68
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
what causes damage to melanocytes and their progressive with occasional flares. Hair is
consequent disappearance in affected skin. There affected in later stages. There is a frequently
are several pathophysiologic theories as associated personal or family history of
explained earlier, but no one is exclusive, and it autoimmune disorders.19 Koebnerization and
is likely that each of them partially contribute. nonsegmental subtypes are associated with
The current thought is that vitiligo represents a disease progression in patients not receiving
group of varied pathophysiologic disorders with therapy.20,21 Rare types of vitiligo include
a similar phenotype. The convergence theory ponctué which manifests as discrete, confetti-
explains that stress, accumulation of toxic like amelanotic macules which occur on normal
compounds, infection, autoimmunity, mutations, or hyperpigmented skin.22 Trichrome vitiligo is
altered cellular environment, and impaired also a rare type, represents a tan zone of varying
melanocyte migration can all contribute to width between normal and depigmented skin.23
pathogenesis.9 Autoimmune mechanisms are the
likely cause of generalized vitiligo, while a more Associated diseases
localized phenomenon as focal or segmental
vitiligo is likely to be a result of neurohumoral Vitiligo may be associated with other
mechanisms.10 New theories, such as autoimmune disorders especially autoimmune
melanocytorrhagy and decreased melanocyte thyroid disorders as hypothyroidism and
survival, are also under consideration.11,12 hyperthyroidism. They may present in as many
as 24% of pediatric vitiligo patients,24-26 although
Cutaneous manifestations the onset is typically delayed by more than a
decade.27 Other associated AI disorders include
Vitiligo is a disorder of pigmentation diabetes, pernicious anemia, and psoriasis.28
manifesting as symmetrically distributed white Vitiligo may also be associated with
macules and patches. It can occur at any age and ophthalmologic and auditory abnormalities such
has no gender bias. It is typically asymptomatic. as uveitis, iritis and hearing loss.29,30,31 Moreover,
Vitiligo is classified into three types: localized, vitiligo is also known to be associated with
generalized, and universal.13,14 Localized vitiligo several syndromes, including autoimmune
is further subtyped into focal, segmental(SV) polyendocrinopathy candidiasis- ectodermal
(dermatomal or Blaschko-linear), and mucosal15. dysplasia syndrome, Vogt-Koyanagi-Harada
Generalized vitiligo may be further subclassified syndrome, Alezzandrini’s syndrome, and
as acrofacial, vulgaris or mixed. Universal Schmidt syndrome.32-38
vitiligo involves more than 80% of the skin.
Generalized vitiligo is the most common type, Diagnosis
and vulgaris is the most common subtype. The
common sites for vitiligo vulgaris are the fingers The diagnosis of vitiligo is usually made
and wrists, axillae, groin and body orifices, such clinically. Wood’s lamp may be of use in
as the mouth, eyes, and genitals.15,16,17 SV usually determining extent and activity of vitiligo, as
begins in childhood18,19 and most commonly well as monitoring response to therapy and the
affects trigeminal dermatome and tends to progress of lesions over time.15,39 Recommended
remain stable.16,18 Generalized vitiligo may begin evaluation checklist for the management of
later in life, and at sites which are sensitive to patients with nonsegmental is given in Box 1
pressure, friction, and/or trauma. It is typically and 2.40
69
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
Box 1 Checklist for assessment of vitiligo patient whereas various treatment options are discussed
• Skin phototype in upcoming sections.
• Duration of disease (progressive or regressive,
stable over the last 6 months)
• Premature hair greying (i) Corticosteroids
• Age at onset
• Genitals involvement Topical corticosteroids (TCS) are most effective
• Type and duration of previous treatments and as monotherapy41 and produce the best clinical
ongoing treatment
• Previous spontaneous repigmentation outcomes especially when combined with light
• Koebner phenomenon therapy.42 In children and adults, topical
• History of autoimmune disease in family corticosteroid can be advised for the patients
including vitiligo
with limited, extrafacial involvement for a
• Thyroid function tests (in adults),
polyglandular syndromes may be suspected in period no longer than 3 months, according to a
such cases daily application therapy.15,40 An alternate day
• Photographs may be required for monitoring application therapy (15 days per month for 6
treatment response.
• Comorbid conditions and their treatment list
months with a strict assessment of response
• Psychological status and quality of life of the based on photographs preferably) is a better
patients option.40 As potent topical corticosteroids appear
to be at least as effective as very potent topical
Box 2 Diagnosis of vitiligo
1. Special cases corticosteroid so, the first category should be the
• Anti-thyroid peroxidase antibodies safest choice.43 Systemic absorption and skin
• Antithyroglobulin antibodies atrophy is a concern when large areas of skin are
• TSH and other tests if needed to assess
involved, regions with thin skin and children
thyroid function
• Additional autoantibodies (only if patient’s who are treated for a prolonged time with potent
history, family history and ⁄ or laboratory steroids. In such cases, topical corticosteroids
parameters point to a strong risk of with negligible systemic effects, such as
additional autoimmune disease)
• Endocrinologist ⁄immunologist advice if mometasone furoate or methylprednisolone
multiple autoimmune syndrome considered aceponate should be preferred.40 Systemic
2. Uncertain diagnosis corticosteroids therapy is not considered useful
• Punch biopsy from lesional and nonlesional
for repigmenting stable vitiligo. However, they
skin
can arrest activity of the disease.17 Weekend oral
Management mini-pulse (OMP) starting with low doses (2.5
mg daily) of dexamethasone for fast-spreading
Younger patients, those with recent onset of the vitiligo can be considered, with a good tolerance
disease, darker skin types, and lesions of the profile. The optimal duration of OMP therapy
face, neck, and trunk tend to respond best to the needed to stop vitiligo progression is between 3
treatment. Segmental type of vitiligo is non and 6 months. Methylprednisolone 40-60mg
progressive, but it does not respond well to the intramuscular or dexamethasone in stat doses is
treatment. Family history of vitiligo, mucosal also recommended for halting rapidly
involvement and typically acral lesions are progressive vitiligo. Moreover, it must be kept in
associated with the disease progression and are mind that because of the potential side-effects of
resistant to treatment. Table 1 shows a summary these agents (Box 3), their use as first line drugs
is not justified in vitiligo.44,45
70
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
Box 3 Adverse effects of corticosteroids alternative to topical steroids for new, actively
Local adverse effects spreading, lesions on thin skin.46-49 The topical
i) Epidermal atrophy
ii) Telangiectasia safety profile of calcineurin inhibitors (TCI) is
iii) Striae distensae better as compared to potent topical steroids,
iv) Steroid folliculitis especially concerning risks of skin atrophy.
v) Acne
Systemic adverse effects Tacrolimus and pimecrolimus are topical
1. Insomnia ascomycin immunomodulating macrolactams
2. Agitation (TIM) and act as TCI, affecting the activation
3. Menstrual disturbances
4. Weight gain and maturation of T cells and subsequently
5. Hypertrichosis inhibiting the production of cytokines, such as
6. Hypertension tumour necrosis factor (TNF)-α. Moreover, they
7. Diabetes
8. Cataract
also enhance melanocyte migration and
9. Adrenal insufficiency differentiation. The use of TIM should be
restricted to selected areas, in particular the head
Box 4 Adverse effects of calcineurin inhibitors and neck region. Twice-daily applications are
• Mild burning or irritations
• Reactivation of herpes simplex recommended. The treatment should be
• Skin hyperpigmentation prescribed initially for 6 months, which can be
• Main limitation in use of TIM is its cost prolonged to 12 months safely.50,51,52 Common
Adverse effects are mentioned in Box 4.53
(ii) Calcineurin inhibitors
(iii) Vitamin D3 analogues
Topical immunomodulators (TIM) can be safely
used in adults and children with vitiligo as an Vitamin D3 analogues act via
71
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
72
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
73
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
combination therapy appears to be at best combination, and Ginkgo biloba are antioxidants
very limited.76 that have been used alone or, more frequently, in
4. TCS and TIM/vitamin D3 analogues This combination with phototherapy.82 The safety
combination provides better results in profiles of many antioxidants are unknown.
vitiligo.76 Topical catalase/superoxide dismutase causes
5. Phototherapy after surgery There is now a transient erythema, pruritus, and peeling.83
good level of evidence that phototherapy
(NB-UVB or PUVA) should be used for 3 (vii) Surgery
or 4 weeks after surgical procedures to
enhance repigmentation.77,78 This option should be reserved for patients with
SV and other localized forms, or after the
(v) Lasers documented failure of medical options. Various
methods being used are melanocyte transplant
The mechanism of action is thought to be similar techniques such as suction blister grafting, split-
to conventional light therapy, but lasers allow thickness grafting, punch grafting, and
targeted treatment, less total body irradiation, melanocyte suspension.81
and fewer side effects on healthy skin. The
monochromatic excimer laser (308 nm) allows (viii) Other interventions
for the targeted treatment of specific lesions and
yields better results than conventional light (a) Camouflage Considering the impact of the
therapy.79 Mild erythema and pruritus are disease on the patient’s personality, camouflage
reported.80 It is recommended as one to three techniques are an important part of the
times a week for twelve weeks. A new device management of the disease. There is a wide
from Italy, known as Bioskin®, emits focused choice of self-tanning agents, stains, dyes,
311nm UVB phototherapy (microphototherapy). whitening lotions, tinted cover creams, compact,
The aim is to improve cosmesis, reduce adverse liquid and stick foundations, fixing powders,
effects, and decrease the premature aging and fixing sprays, cleansers, and dyes for pigmenting
risk of skin cancer associated with total body facial and scalp white hair.84
irradiation.7 Helium neon laser (632.8 nm)
therapy is effective for segmental vitiligo. It (b) Depigmentation Only patients with extensive
promotes melanogenesis, melanocyte growth, vitiligo should be offered this option and only
migration, and survival in the skin.81 after exploring other possible therapies.
Monobenzone is the topical agent used for this
(vi) Antioxidants purpose. The patient should be advised that
monobenzone is a potent depigmenting agent
Oxidative stress has recently been implicated in and not a cosmetic skin bleach. Depigmentation
the pathogenesis of vitiligo. Antioxidant can also be obtained by using a Q-switched ruby
supplementation oral or topical can be useful or alexandrite laser, alone or in combination
during UV therapy, and also during the with topical depigmenting agents. Monobenzone
reactivation phase of vitiligo. However, further may cause burning, itching, and contact
research is required. Pseudocatalase, vitamin E, dermatitis.85 Conjunctival melanosis,
vitamin C, ubiquinone, lipoic acid, Polypodium pingueculae, and corneal pigment deposition
leucotomos, catalase⁄superoxide dismutase have been reported with monobenzone.86
74
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
(ix) New concepts in treating vitiligo Targeted and combination treatment for
vitiligo. Comparative evaluation of different
current modalities in 458 subjects. Dermatol
Psychotherapy helps the psychosocial effects of Ther. 2008;21:S20-6.
vitiligo, but may also cause disease regression.87 8. Taieb A, Picardo M. Clinical practice.
Tumor necrosis factor-α inhibitors are reported Vitiligo. N Engl J Med. 2009;360:160-9.
9. Le Poole IC, Das PK, van den Wijngaard
to alter disease progression of vitiligo, but this RM et al. Review of the
has yet to be studied in clinical trials.88 A recent etiopathomechanism of vitiligo: a
study suggests that minocycline may halt disease convergence theory. Exp Dermatol.
1993;2:145-53.
progression.89 Immunosuppressants 10. Hann SK, Lee HJ. Segmental vitiligo:
(azathioprine, cyclophosphamide and clinical findings in 208 patients. J Am Acad
cyclosporine) may have a role in the treatment of Dermatol. 1996;35:671-4.
11. Kitamura R, Tsukamoto K, Harada K et al.
vitiligo. But, still more data are required.90
Mechanisms underlying the dysfunction of
melanocytes in vitiligo epidermis: role of
Recommendations SCF/KIT protein interactions and the
downstream effector, MITF-M. J Pathol.
2004;202:463-75.
Treatment of vitiligo should be started with less 12. Le Poole IC, van den Wijngaard RM,
aggressive and cost-effective modalities, Westerhof W, Das PK. Tenascin is
reserving more invasive and expensive options overexpressed in vitiligo lesional skin and
inhibits melanocyte adhesion. Br J
for those who fail to respond to first-line Dermatol. 1997;137:171-8.
therapy. Treatment algorithm is also 13. Shajil EM, Chatterjee S, Agrawal D et al.
recommended. Vitiligo: pathomechanisms and genetic
polymorphism of susceptible genes. Indian J
Exp Biol. 2006;44:526-39.
References 14. Nordlund JJ, Lerner AB. Vitiligo. It is
important. Arch Dermatol. 1982;118:5-8.
1. Fai D, Cassano N, Vena GA. Narrow-band 15. Gawkrodger DJ, Ormerod AD, Shaw L et al.
UVB phototherapy combined with Guideline for the diagnosis and management
tacrolimus ointment in vitiligo: a review of of vitiligo. Br J Dermatol. 2008;159:1051-
110 patients. J Eur Acad Dermatol 76.
Venereol. 2007;21:916-20. 16. Halder RM, Taliaferro SJ. Vitiligo. In:
2. Nicolaidou E, Antoniou C, Stratigos A, Wolff K, Goldsmith L, Katz S et al., editors.
Katsambas AD. Narrowband ultraviolet B Fitzpatrick’s Dermatology in General
phototherapy and 308-nm excimer laser in Medicine. New York: McGraw-Hill; 2008.
the treatment vitiligo: A review. J Am Acad p. 616-22.
Dermatol. 2009;60:470-7. 17. Arycan O, Koc K, Ersoy L. Clinical
3. Majid I. Vitiligo Management: An Update. characteristics in 113 Turkish vitiligo
Br J Med Practit. 2010;3:1-6. patients. Acta Dermatovenerol Alp Panonica
4. Mattoo SK, Handa S, Kaur I et al. Adriat. 2008;17:129-32.
Psychiatric morbidity in vitiligo: prevalence 18. Hann SK, Lee HJ. Segmental vitiligo:
and correlates in India. J Eur Acad Dermatol clinical findings in 208 patients. J Am Acad
Venereol. 2002;16:573-8. Dermatol. 1996;35:671-4.
5. Aghaei S, Sodaifi M, Jafri P et al. DLQI 19. Barona MI, Arrunategui A, Falabella R,
scores in vitiligo: reliability and validity of Alzate A. An epidemiologic case-control
the Persian version. BMC Dermatol. study in a population with vitiligo. J Am
2004;**4-8. Acad Dermatol. 1995;33:621-5.
6. Habib A, Sheikh ZI, Khan Q, Rahman SB. 20. Mazereeuw-Hautier J, Bezio S, Mahe E et
Efficacy and safety of oral dexamethasone al. Segmental and nonsegmental childhood
pulse treatment for vitiligo. Pak Armed vitiligo has distinct clinical characteristics: a
Forces Med J. 2006;56: 111-5. prospective observational study. J Am Acad
7. Lotti T, Buggiani G, Troiano M et al. Dermatol. 2010;62:945-9.
75
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
21. Chun WH, Hann SK. The progression of Koyanagi-Harada disease in Hispanic
nonsegmental vitiligo: clinical analysis of patients. Int Ophthalmol. 2007;27:143-8.
318 patients. Int J Dermatol. 1997;36:908- 36. Tesavibul N, Sansanayuth W. Vogt-
10. Koyanagi-Harada disease in Thai patients. J
22. Ortonne J-P, Passeron T. Vitiligo and other Med Assoc Thai. 2005;88(suppl 9):S26-30.
disorders of hypopigmentation. In: Bolognia 37. Rathinam SR, Vijayalakshmi P,
J, Jorizzo J, Rapini R, editors. Dermatology, Namperumalsamy P et al. Vogt-Koyanagi-
3rd edn. Philadelphia: Mosby Elsevier; 2012. Harada syndrome in children. Ocul Immunol
p. 1023-48. Inflamm. 1998;6:155-61.
23. Hann SK, Kim YS, Yoo JH, Chun YS. 38. Boutimzine N, Laghmari A, Ouazzani I et
Clinical and histopathologic characteristics al. Vogt-Koyanagi-Harada syndrome.
of trichrome vitiligo. J Am Acad Dermatol. Epidemiological, clinical and disease
2000;42:589-96. progression aspects. Twenty cases [in
24. Pagovich OE, Silverberg JI, Freilich E, French]. J Fr Ophthalmol. 1998;21:746-5.
Silverberg NB. Thyroid abnormalities in 39. Ardigo M, Malizewsky I, Dell’anna ML et
pediatric patients with vitiligo in New York al. Preliminary evaluation of vitiligo using
City. Cutis. 2008;81:463-6. in vivo reflectance confocal microscopy. J
25. Iacovelli P, Sinagra JL, Vidolin AP et al. Eur Acad Dermatol Venereol.
Relevance of thyroiditis and of other 2007;21:1344-50.
autoimmune diseases in children with 40. Taiebi A, Alomar A, Bohm M et al.
vitiligo. Dermatology. 2005;210:26-30. Guidelines for the management of vitiligo:
26. Kakourou T, Kanaka-Gantenbein C, the European Dermatology Forum
Papadopoulou A et al. Increased prevalence consensus. Br J Dermatol. 2013;168:5-9.
of chronic autoimmune (Hashimoto’s) 41. Kandil E. Treatment of vitiligo with 0-1 per
thyroiditis in children and adolescents with cent betamethasone 17-valerate in isopropyl
vitiligo. J Am Acad Dermatol. 2005;53:220- alcohol—a double-blind trial. Br J
3. Dermatol. 1974;91:457-60.
27. Dittmar M, Kahaly GJ. Polyglandular 42. Westerhof W, Nieuweboer-Krobotova L,
autoimmune syndromes: immunogenetics Mulder PG, Glazenburg EJ. Left-right
and long-term follow-up. J Clin Endocrinol comparison study of the combination of
Metab. 2003;88:2983-92. fluticasone propionate and UV-A vs. either
28. Powell FC, Dicken CH. Psoriasis and fluticasone propionate or UV-A alone for
vitiligo. Acta Derm Venereol. 1983;63:246- the long-term treatment of vitiligo. Arch
9. Dermatol. 1999;135:1061-6.
29. Hong CK, Lee MH, Jeong KH et al. Clinical 43. Grimes PE, Morris R, Avaniss-Aghajani E
analysis of hearing levels in vitiligo patients. et al. Topical tacrolimus therapy for vitiligo:
Eur J Dermatol. 2009;19:50-6. therapeutic responses and skin messenger
30. Gopal KV, Rama Rao GR, Kumar YH et al. RNA expression of proinflammatory
Vitiligo: a part of a systemic autoimmune cytokines. J Am Acad Dermatol.
process. Indian J Dermatol Venereol Leprol. 2004;51:52-61.
2007;73:162-5. 44. Kwinter J, Pelletier J, Khambalia A, Pope E.
31. Flynn GE. Bilateral uveitis, poliosis, and High-potency steroid use in children with
vitiligo; with a hereditary factor. Am J vitiligo: a retrospective study. J Am Acad
Ophthalmol. 1952;35:568-72. Dermatol. 2007;56:236-41.
32. Tsuruta D, Hamada T, Teramae H et al. 45. Lepe V, Moncada B, Castanedo-Cazares JP
Inflammatory vitiligo in Vogt-Koyanagi- et al. A double-blind randomized trial of
Harada disease. J Am Acad Dermatol. 0.1% tacrolimus vs 0.05% clobetasol for the
2001;44:129-31. treatment of childhood vitiligo. Arch
33. Wong SS, Ng SK, Lee HM. Vogt-Koyanagi- Dermatol. 2003;139:581-5.
Harada disease: extensive vitiligo with 46. Kandil E. Treatment of vitiligo with 0-1 per
prodromal generalized erythroderma. cent betamethasone 17-valerate in isopropyl
Dermatology. 1999;198:65-8. alcohol—a double-blind trial. Br J
34. Barnes L. Vitiligo and the Vogt-Koyanagi- Dermatol. 1974;91:457-60.
Harada syndrome. Dermatol Clin. 47. Radakovic-Fijan S, Furnsinn-Friedl AM,
1988;6:229-39. Honigsmann H, Tanew A. Oral
35. Sukavatcharin S, Tsai JH, Rao NA. Vogt- dexamethasone pulse treatment for vitiligo.
76
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
77
Journal of Pakistan Association of Dermatologists. 2014;24 (1):68-78.
78